[go: up one dir, main page]

IT1248075B - Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. - Google Patents

Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Info

Publication number
IT1248075B
IT1248075B ITMI911662A ITMI911662A IT1248075B IT 1248075 B IT1248075 B IT 1248075B IT MI911662 A ITMI911662 A IT MI911662A IT MI911662 A ITMI911662 A IT MI911662A IT 1248075 B IT1248075 B IT 1248075B
Authority
IT
Italy
Prior art keywords
virus
hepatitis
hav
contain
purification process
Prior art date
Application number
ITMI911662A
Other languages
English (en)
Inventor
Vittoria Pellegrini
Nicoletta Fineschi
J Arie Zuckerman
Original Assignee
Sclavo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sclavo Spa filed Critical Sclavo Spa
Publication of ITMI911662A0 publication Critical patent/ITMI911662A0/it
Priority to ITMI911662A priority Critical patent/IT1248075B/it
Priority to EP92109524A priority patent/EP0522291B1/en
Priority to ES92109524T priority patent/ES2104771T3/es
Priority to DK92109524.6T priority patent/DK0522291T3/da
Priority to DE69221225T priority patent/DE69221225T2/de
Priority to AT92109524T priority patent/ATE156187T1/de
Priority to JP4181643A priority patent/JPH07177882A/ja
Publication of ITMI911662A1 publication Critical patent/ITMI911662A1/it
Priority to US08/276,780 priority patent/US5607851A/en
Application granted granted Critical
Publication of IT1248075B publication Critical patent/IT1248075B/it
Priority to US08/457,310 priority patent/US5719049A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

E' descritto un processo per la purificazione del virus dell'epatite A che consente di ottenere un prodotto puro con buone rese in cui il materiale organico raccolto per centrifugazione dopo la lisi delle cellule di coltura viene sottoposto a gel filtrazione e successivamente a cromatografia a scambio ionico.
ITMI911662A 1991-06-18 1991-06-18 Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. IT1248075B (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ITMI911662A IT1248075B (it) 1991-06-18 1991-06-18 Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
DE69221225T DE69221225T2 (de) 1991-06-18 1992-06-05 Verfahren zum Reinigen von Hepatits-A-Virus (HAV), so gereinigter Virus und Impfstoffzusammensetzungen, die ihn enthalten
ES92109524T ES2104771T3 (es) 1991-06-18 1992-06-05 Procedimiento para purificar el virus de la hepatitis a (vha), el virus de dicha forma purificado y composiciones de vacunas que los contienen.
DK92109524.6T DK0522291T3 (da) 1991-06-18 1992-06-05 Fremgangsmåde til rensning af hepatitis A-virus (HAV), således renset virus og vaccinepræparater indeholdende dette
EP92109524A EP0522291B1 (en) 1991-06-18 1992-06-05 Process for purifying hepatitis a virus (HAV), virus thus purified and vaccine compositions containing it
AT92109524T ATE156187T1 (de) 1991-06-18 1992-06-05 Verfahren zum reinigen von hepatits-a-virus (hav), so gereinigter virus und impfstoffzusammensetzungen, die ihn enthalten
JP4181643A JPH07177882A (ja) 1991-06-18 1992-06-17 Ａ型肝炎ウイルス（ｈａｖ） の精製方法、こうして精製されたウイルス及びそれを含むワクチン組成物
US08/276,780 US5607851A (en) 1991-06-18 1994-07-18 Process for purifying hepatitis a virus (HAV), and vaccine compositions containing hepatitis a virus
US08/457,310 US5719049A (en) 1991-06-18 1995-06-01 Process for purifying hepatitis A virus (HAV), virus thus purified and vaccine compositions containing it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911662A IT1248075B (it) 1991-06-18 1991-06-18 Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Publications (3)

Publication Number Publication Date
ITMI911662A0 ITMI911662A0 (it) 1991-06-18
ITMI911662A1 ITMI911662A1 (it) 1992-12-18
IT1248075B true IT1248075B (it) 1995-01-05

Family

ID=11360137

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI911662A IT1248075B (it) 1991-06-18 1991-06-18 Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Country Status (8)

Country Link
US (2) US5607851A (it)
EP (1) EP0522291B1 (it)
JP (1) JPH07177882A (it)
AT (1) ATE156187T1 (it)
DE (1) DE69221225T2 (it)
DK (1) DK0522291T3 (it)
ES (1) ES2104771T3 (it)
IT (1) IT1248075B (it)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
ATE353956T1 (de) * 1996-12-13 2007-03-15 Schering Corp Methoden zur virus-reinigung
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6855535B2 (en) * 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CN101080488A (zh) * 2004-11-03 2007-11-28 因特罗根治疗公司 生产和纯化腺病毒载体的新方法
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
CN102257134B (zh) * 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
CN102985536B (zh) 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
CN101816786B (zh) * 2010-04-30 2012-09-05 长春生物制品研究所有限责任公司 一种甲型肝炎灭活疫苗及其制备方法
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3695849A1 (en) 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture
JP6898535B1 (ja) * 2020-06-16 2021-07-07 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 アパタイトカラムを使用したウイルスの精製方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
JPS6147186A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
US4673634A (en) * 1985-03-08 1987-06-16 The United States Of America As Represented By The Department Of Health And Human Services Purified antigen from non-A, non-B hepatitis causing factor
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
EP0327801A1 (en) * 1988-01-08 1989-08-16 Deutsches Primatenzentrum Gesellschaft Mbh HIV-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン

Also Published As

Publication number Publication date
ATE156187T1 (de) 1997-08-15
ES2104771T3 (es) 1997-10-16
JPH07177882A (ja) 1995-07-18
EP0522291B1 (en) 1997-07-30
EP0522291A1 (en) 1993-01-13
US5607851A (en) 1997-03-04
ITMI911662A1 (it) 1992-12-18
DE69221225D1 (de) 1997-09-04
DK0522291T3 (da) 1997-08-18
DE69221225T2 (de) 1998-03-19
ITMI911662A0 (it) 1991-06-18
US5719049A (en) 1998-02-17

Similar Documents

Publication Publication Date Title
IT1248075B (it) Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
DK0620847T3 (da) Fremstilling af renkulturer af post-mitotiske humane neuroner
BE885269A (fr) Nouveaux tensio-actifs non ioniques, leur procede de preparation et composition les contenant
DK0424047T3 (da) Vævskulturfremgangsmåde til transformation af planteceller
BE889683A (fr) Nouveaux oligomeres tensio-actifs, leur procede de preparation et les compositions les contenant
IT1196549B (it) Procedimento per la produzione del fattore di lisi cellule bersaglio (tclf),prodotto ottenuto a suo impiego in terapia clinica,in particolare come agente citolitico antitumurale
DK299887D0 (da) Fremgangsmaade til fremstilling af sterile pyrogenfrie farmaceutiske praeparater af ligeret radioaktivt rhenium og materialesaet til anvendelse ved fremgangsmaaden
IT1238348B (it) Processo per la preparazione di costrutti genetici per l'espressione del fattore di crescita nervoso in cellule eucariote.
FR2487642B2 (fr) Procede de preparation de fractions proteiques par ultrafiltration et chromatographie d'exclusion et d'echange d'ions
DE3786806D1 (de) Reinigung von keuchhustenantigenen.
ES2093031T3 (es) Metodo para purificar el factor de crecimiento transformante (tgf).
EA200200109A1 (ru) Кристаллы динуклеотида
ES546381A0 (es) Nuevas butirolactamas, composiciones farmacologicamente activas de las mismas, procedimientos para su obtencion y su empleo en medicina.
CO4480040A1 (es) Proceso de purificacion del antigeno de superficie viral hepatitis b que comprende el peptido pres 2
IT1099161B (it) Processo per la preparazione di granulati dotati di attivita' biologica
DK0491733T3 (da) Somatisk embryogenese af græskar
BG44029A3 (en) Method for preparing of n- dimethyl morphinanic derivatives
MA20926A1 (fr) Composes heterocycliques azotes nouveaux, compositions les contenant, leur preparation et leur application pour reduire la perte d'humidite de plantes et pour accroitre le rendement de cultures.
DK461987D0 (da) Fremgangsmaade til adskillelse af diastereomere.
DK576286D0 (da) Fremgangsmaade til halvkontinuerlig metabolitproduktion ved hjaelp af planteceller, dyrket in vitro
SU1108106A1 (ru) Способ получени эндонуклеазы рестрикции @ 1
FR2411614A2 (fr) Procede de fabrication d'un generateur d'oxygene chimique et generateur d'oxygene chimique realise selon ce procede
BE895365A (fr) Procede d'amelioration du rendement dans la multiplication in vitro de plantes cultivees
RU94004840A (ru) Штамм вируса классической чумы свиней, используемый для изготовления вакцины
FR2616430B1 (fr) Nouveaux diesters de l'acide azelaique, leur procede de preparation, les compositions topiques les contenant et leur utilisation dans le traitement de l'acne

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970626